“Lipid profile in people starting antiretroviral therapy with efavirenz or dolutegravir based regimens from a reference center in Brazil: a cohort study” (2022) Research, Society and Development, 11(5), p. e55811528662. doi:10.33448/rsd-v11i5.28662.